These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 26460589)
21. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. Cai H; Li L; Jiang J; Zhao C; Yang C Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974 [TBL] [Abstract][Full Text] [Related]
22. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065 [TBL] [Abstract][Full Text] [Related]
23. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway. Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993 [TBL] [Abstract][Full Text] [Related]
24. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. Lin KN; Jiang YL; Zhang SG; Huang SY; Li H Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917 [TBL] [Abstract][Full Text] [Related]
25. Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein. Sun Y; Liu W; Wang C; Meng Q; Liu Z; Huo X; Yang X; Sun P; Sun H; Ma X; Peng J; Liu K J Cell Physiol; 2019 Apr; 234(4):3685-3696. PubMed ID: 30171603 [TBL] [Abstract][Full Text] [Related]
26. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. Zhang HR; Chen JM; Zeng ZY; Que WZ J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505 [TBL] [Abstract][Full Text] [Related]
27. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
28. Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways. Zhang L; Zhang Z; Chen F; Chen Y; Lin Y; Wang J Eur J Med Chem; 2016 Nov; 123():226-235. PubMed ID: 27484511 [TBL] [Abstract][Full Text] [Related]
29. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway. Wang Q; Zhang X; Song X; Zhang L Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142 [TBL] [Abstract][Full Text] [Related]
30. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176 [TBL] [Abstract][Full Text] [Related]
31. Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Wang H; Jia XH; Chen JR; Wang JY; Li YJ Oncol Rep; 2016 Jun; 35(6):3659-68. PubMed ID: 27109742 [TBL] [Abstract][Full Text] [Related]
32. Reversal of human multi-drug resistance leukaemic cells by stemofoline derivatives via inhibition of P-glycoprotein function. Umsumarng S; Pitchakarn P; Sastraruji K; Yodkeeree S; Ung AT; Pyne SG; Limtrakul P Basic Clin Pharmacol Toxicol; 2015 May; 116(5):390-7. PubMed ID: 25265513 [TBL] [Abstract][Full Text] [Related]
33. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling. Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325 [TBL] [Abstract][Full Text] [Related]
34. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
35. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved. Bian P; Hu W; Liu C; Li L Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316 [TBL] [Abstract][Full Text] [Related]
36. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Song YN; Guo XL; Zheng BB; Liu XY; Dong X; Yu LG; Cheng YN Toxicol In Vitro; 2011 Jun; 25(4):937-43. PubMed ID: 21402141 [TBL] [Abstract][Full Text] [Related]
37. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Cordo Russo RI; García MG; Alaniz L; Blanco G; Alvarez E; Hajos SE Int J Cancer; 2008 Mar; 122(5):1012-8. PubMed ID: 17985348 [TBL] [Abstract][Full Text] [Related]
38. Involvement of the PI3K/Akt/Nrf2 Signaling Pathway in Resveratrol-Mediated Reversal of Drug Resistance in HL-60/ADR Cells. Li Y; Guo Y; Feng Z; Bergan R; Li B; Qin Y; Zhao L; Zhang Z; Shi M Nutr Cancer; 2019; 71(6):1007-1018. PubMed ID: 31032633 [TBL] [Abstract][Full Text] [Related]
39. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling. Yu J; Chen WX; Xie WJ; Chen RW; Lin DQ; You WW; Ye WL; Zhang HQ; Lin DH; Xu JP J Clin Lab Anal; 2021 Aug; 35(8):e23817. PubMed ID: 34114685 [TBL] [Abstract][Full Text] [Related]
40. Resveratrol induces cell cycle arrest in human gastric cancer MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway. Jing X; Cheng W; Wang S; Li P; He L Oncol Rep; 2016 Jan; 35(1):472-8. PubMed ID: 26530632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]